Nachrichten zur Akero Therapeutics Aktie

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lincoln, Compass Minerals, Exscientia, and Akero and Encourages Investors to Contact the Firm

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Abraham, Fruchter & Twersky LLP Notifies Shareholders of a Class Action Lawsuit on Behalf of Investors who Acquired Shares of Akero Therapeutics, Inc. (NYSE: AKRO)

Abraham, Fruchter & Twersky, LLP, informs shareholders of a class action lawsuit on behalf of investors who purchased Akero Therapeutics,…

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Akero Therapeutics, Inc. - AKRO

CEDARHURST, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues…

Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company…

AKRO INVESTOR ALERT: Edelson Lechtzin LLP Urges Akero Therapeutics, Inc. (NASDAQ: AKRO) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action

Edelson Lechtzin LLP is investigating securities fraud claims on behalf of investors in Akero Therapeutics, Inc. (NASDAQ: AKRO)…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, Akero, Equinix, and Harbor Diversified and Encourages Investors to Contact the Firm

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

AKRO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges Akero Therapeutics, Inc. Investors with Losses to Contact the Firm

Radnor, Pa., May 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

Contact Hagens Berman by June 25, 2024 Deadline to Join Class Action Against Akero Therapeutics (AKRO)

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who…

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a…

AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO

NEW ORLEANS, May 07, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, Akero, and Equinix and Encourages Investors to Contact the Firm

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO

NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Kessler Topaz Meltzer & Check, LLP - Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc.

RADNOR, Pa., May 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

SAN DIEGO, May 04, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that it has…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, and Akero and Encourages Investors to Contact the Firm

NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors

NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP announces that a…

Akero Therapeutics (AKRO) Slides After Failed Trial, Hit With Class Action Lawsuit – Hagens Berman

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who…

AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…

AKRO INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO

NEW ORLEANS, April 30, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former…

AKERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc. (AKRO)

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action…

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm

The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm…

AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Akero Class Action Lawsuit

SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that it has…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Akero Therapeutics EFX Data Warrants Caution

…

Akero Therapeutics executive sells over $20k in company stock By Investing.com

Akero Therapeutics executive sells over $20k in company stock…

Akero Therapeutics CFO sells shares to cover tax withholding By Investing.com

Akero Therapeutics CFO sells shares to cover tax withholding…

Akero Therapeutics COO sells shares worth over $18,000 By Investing.com

Akero Therapeutics COO sells shares worth over $18,000…

Akero Therapeutics CEO sells over $55k in company stock By Investing.com

Akero Therapeutics CEO sells over $55k in company stock…

Akero Therapeutics CSO sells shares worth over $17k By Investing.com

Akero Therapeutics CSO sells shares worth over $17k…

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational…

dpa-AFX ProFeed